RCKT — ROCKET PHARMACEUTICALS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1281895 ·
Last close
$2.11
Market Cap
$235.60M
52W High
$5.45
52W Low
$2.03
ADV30
1,943,728
Next earnings
2026-11-12
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -50,965,000 -49,234,000 419,504,000 95,470,000 92,780,000
Jun 2026 0 — -46,922,000 123,214,000 423,098,000 224,507,000 54,268,000
Mar 2026 0 — -48,511,000 -47,594,000 285,407,000 49,610,000 47,368,000
Dec 2025 0 — -44,031,000 -42,538,000 330,449,000 77,558,000 53,228,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-170,267,000
Investing CF
$361,849,000
Financing CF
$82,000
CapEx
$-231,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.17
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,365,619,000
Inventory
—
Receivables
—
ST Investments
$59,240,000
EBIT TTM
$-6,737,000
Pretax Income TTM
$-8,629,000
Interest Exp TTM
$1,892,000
Analysts
11

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -228,516,000 -223,123,000 330,449,000 53,228,000 277,221,000 -190,014,000
Dec 2024 0 -273,205,000 -258,746,000 527,700,000 64,466,000 463,234,000 -209,724,000
Dec 2023 0 -259,659,000 -245,595,000 566,341,000 73,767,000 492,574,000 -194,916,000
Dec 2022 0 -223,843,000 -221,863,000 551,807,000 62,121,000 489,686,000 -178,142,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-17,250,000
OpCashFlow TTM
—
Assets (Latest)
$423,098,000
Forward EPS
$-1.57

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $2.11 · call volume: 29 · put volume: 5
Expected Move to 2027-01-15: ±$0.71 (33.65%) — implied range $1.40 – $2.82 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BIOA BioAge Labs, Inc. $234.35M $5.10 —
FTH Faeth Therapeutics, Inc. $233.63M $9.04 —
VNDA Vanda Pharmaceuticals Inc. $230.39M $3.81 —
ARCT Arcturus Therapeutics Holdings Inc. $229.72M $7.97 —
LFCR LIFECORE BIOMEDICAL, INC. \DE\ $242.22M $6.39 —

News headlines (Yahoo Finance, 1h cache)

Rocket Pharmaceuticals: Q3 Earnings Snapshot
2026-11-12 21:10 · Yahoo
Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress
2026-11-12 21:00 · Yahoo
Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
2026-10-15 11:00 · Yahoo
Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility
2026-10-07 15:36 · Yahoo
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
2026-10-07 13:36 · Yahoo
Rocket receives $150m credit facility to advance cardiovascular portfolio
2026-10-07 10:42 · Yahoo
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
2026-10-07 02:02 · Yahoo
Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?
2026-09-22 23:52 · Yahoo
Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock
2026-09-16 12:07 · Yahoo
Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial
2026-09-15 14:21 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.